.png)
ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial...
Dsn.sebani Ds.tanjangrono RT 04 RW 01 Mojokerto-Jawa Timur
+6281993868686
lita@gdrive.or.id
Copyright © 2023 saktinews. All Rights Reserved
